The Department of Health and Social Care announced that all babies born in England will undergo screening for spinal muscular atrophy (SMA), a rare muscle-wasting disease, starting in October 2027. The condition affects approximately one in 10,000 babies, with roughly 48 cases identified annually across the UK. Early detection enables access to effective gene-therapy treatment that can prevent the onset of debilitating symptoms.
SMA causes significant physical impairment in affected infants, including muscular weakness, mobility limitations, and breathing and swallowing difficulties. Without diagnosis, the condition can be fatal within two years. Current plans will integrate SMA screening into existing newborn testing protocols, where blood samples collected through heel-prick tests at five days of age are already screened for ten other conditions including cystic fibrosis and sickle cell disease.
The announcement represents an expansion of initial plans. A pilot programme announced in April was set to screen approximately 72% of newborns in England beginning in October of this year. That limited approach faced criticism for potentially creating disparities in detection based on geographic location. The universal screening initiative will utilize all 13 laboratories capable of conducting the tests, up from the current seven facilities.
Campaigners and patient advocacy organizations characterized the decision as a significant development for affected families. Officials noted that the expanded programme will cover approximately 560,000 to 570,000 newborns annually across England. The rollout will continue throughout 2027 to ensure all screening laboratories across the country implement testing capacity.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI